Hexal (Germany)

Recent papers from Hexal (Germany)

1. Response to commentary on “An efficient crossover design for thorough QT studies” by Chen & Weng2026
2. P0883Risankizumab versus reference and biosimilar ustekinumab in moderate-to-severe Crohn’s disease: A cost-effectiveness model from the German perspectiveJournal of Crohn s and Colitis · 2026
3. T cell assays for non-clinical immunogenicity risk assessment: best practices recommended by the European Immunogenicity PlatformFrontiers in Immunology · 2026
4. An analysis of cost-saving in the German statutory health insurance system due to the introduction of epoetin alfa biosimilars in GermanyFrontiers in Public Health · 2025
5. Clinical and Real-World Evidence on Etanercept Biosimilar Switching: A Narrative Literature Review of Efficacy and SafetyAdvances in Therapy · 2025
6. Gaboxadol Increases Resting Theta and Alpha Power without Affecting Evoked Responses in Fragile X Syndrome in a Home-based SettingJournal of Neurodevelopmental Disorders · 2025
7. Proceedings of the 26th International Analytical Ultracentrifugation Workshop and SymposiumEuropean Biophysics Journal · 2025
8. Healthy volunteer stem cell donors followed up 10 years after stimulation with biosimilar filgrastimTransfusion · 2025
9. Evaluation of Anti-SARS-CoV-2 IgG Responses in a Clinical Study of a Biosimilar Candidate to Denosumab Using Singlicate AnalysisDrugs in R&D · 2025
10. Immunogenicity risk assessment for tailored mitigation and monitoring of biotherapeutics during development: recommendations from the European Immunogenicity PlatformFrontiers in Immunology · 2025
11. Patient-Reported Outcome Measures in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis Treated with GP2015, an Etanercept Biosimilar: Results from Two Phase III Studies (EGALITY and EQUIRA)Drugs in R&D · 2025
12. Disparities in patient share and characteristics between disease-modifying therapy-treated and -untreated people with multiple sclerosis in Germany: a claims data analysis from 2017 to 2022Frontiers in Neurology · 2025
13. Trial Probability of Success for Testing 3‐Way PK/PD Similarity With Multiple EndpointsPharmaceutical Statistics · 2025
14. Implementation of the Anchor-Based Indirect Comparison Method for Equivalence Margin Derivation in Biosimilar DevelopmentPharmaceuticals · 2025
15. Cardiovascular Safety of GnRH Agonist-Based Androgen Deprivation Therapy in a Real-World Setting: Results from a Prospective Cohort Study (LEAN)Urologia Internationalis · 2025
16. Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature ReviewAdvances in Therapy · 2025
17. The changes necessary in the assessment of immunogenicity for the development of BiosimilarsBioanalysis · 2025
18. Repurposing statins and phenothiazines to treat chemoresistant neuroblastoma2025
19. Cost–consequence analysis of early vs. delayed natalizumab use in highly active relapsing–remitting multiple sclerosis: a simulation studyJournal of Neurology · 2025
20. Development of Biosimilar Aflibercept SDZ-AFLCurrent Therapeutic Research · 2025